Abstract
The ability of recombinant murine (rMu) interferon (IFN) -γ to activate anti-Salmonella-activity in normal mice and beige mutant (bg/bg) mice with Chediak-Higashi syndrome (CHS) was examined. Previous intraperitoneal (i.p.) injection of rMuIFN-γ (104 U per mouse) significantly hindered the bacterial growth in the peritoneal cavities, spleens and livers of the mice after the i.p. infection with Salmonella enteritidis No. 11 strain. It was also effective on the beige mice that have phagocytic cells with a genetically impaired bactericidal function, suggesting that IFN-γ activates the pathway irrelevant to the beige mutation. The effect was the maximum, when IFN-γ was given 6 h before the challenge. The effect seemed to be due to the augmentation of bactericidal capacity rather than the prevention of systemic spread of bacteria. Recombinant human IFN-αA/D (102-106 U per mouse), which produced effects identical to those of murine IFN-β, did not show such a bactericidal effect. Bactericidal activity enhancement was also seen in mice that had been injected with a small amount of rMuIFN-γ (102 U) and bacterial lipopolysaccharide (LPS) (10 ng) together at 6 h before the challenge, although the IFN-γ or LPS alone at these doses produced very little if any effect. Bactericidal effect enhancement was seen in mice that had been injected with IFN-γ at 6 h and LPS at 3 h before the challenge, while it could be hardly seen in mice injected with them in a reversed order. The simultaneous injections of rMuIFN-γ and LPS at 6 h in advance could confer a good protection against the infection with the S. tryphimurium LT2 strain.
| Original language | English |
|---|---|
| Pages (from-to) | 49-56 |
| Number of pages | 8 |
| Journal | International Journal of Immunopharmacology |
| Volume | 12 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Pharmacology
Cite this
Effect of murine recombinant interferon-γ in the protection of mice against salmonella. / Matsumura, Haruo; Onozuka, Kazuyasu; Terada, Yasuhiko; Nakano, Yasunobu; Nakano, Masayasu.
In: International Journal of Immunopharmacology, Vol. 12, No. 1, 1990, p. 49-56.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of murine recombinant interferon-γ in the protection of mice against salmonella
AU - Matsumura, Haruo
AU - Onozuka, Kazuyasu
AU - Terada, Yasuhiko
AU - Nakano, Yasunobu
AU - Nakano, Masayasu
PY - 1990
Y1 - 1990
N2 - The ability of recombinant murine (rMu) interferon (IFN) -γ to activate anti-Salmonella-activity in normal mice and beige mutant (bg/bg) mice with Chediak-Higashi syndrome (CHS) was examined. Previous intraperitoneal (i.p.) injection of rMuIFN-γ (104 U per mouse) significantly hindered the bacterial growth in the peritoneal cavities, spleens and livers of the mice after the i.p. infection with Salmonella enteritidis No. 11 strain. It was also effective on the beige mice that have phagocytic cells with a genetically impaired bactericidal function, suggesting that IFN-γ activates the pathway irrelevant to the beige mutation. The effect was the maximum, when IFN-γ was given 6 h before the challenge. The effect seemed to be due to the augmentation of bactericidal capacity rather than the prevention of systemic spread of bacteria. Recombinant human IFN-αA/D (102-106 U per mouse), which produced effects identical to those of murine IFN-β, did not show such a bactericidal effect. Bactericidal activity enhancement was also seen in mice that had been injected with a small amount of rMuIFN-γ (102 U) and bacterial lipopolysaccharide (LPS) (10 ng) together at 6 h before the challenge, although the IFN-γ or LPS alone at these doses produced very little if any effect. Bactericidal effect enhancement was seen in mice that had been injected with IFN-γ at 6 h and LPS at 3 h before the challenge, while it could be hardly seen in mice injected with them in a reversed order. The simultaneous injections of rMuIFN-γ and LPS at 6 h in advance could confer a good protection against the infection with the S. tryphimurium LT2 strain.
AB - The ability of recombinant murine (rMu) interferon (IFN) -γ to activate anti-Salmonella-activity in normal mice and beige mutant (bg/bg) mice with Chediak-Higashi syndrome (CHS) was examined. Previous intraperitoneal (i.p.) injection of rMuIFN-γ (104 U per mouse) significantly hindered the bacterial growth in the peritoneal cavities, spleens and livers of the mice after the i.p. infection with Salmonella enteritidis No. 11 strain. It was also effective on the beige mice that have phagocytic cells with a genetically impaired bactericidal function, suggesting that IFN-γ activates the pathway irrelevant to the beige mutation. The effect was the maximum, when IFN-γ was given 6 h before the challenge. The effect seemed to be due to the augmentation of bactericidal capacity rather than the prevention of systemic spread of bacteria. Recombinant human IFN-αA/D (102-106 U per mouse), which produced effects identical to those of murine IFN-β, did not show such a bactericidal effect. Bactericidal activity enhancement was also seen in mice that had been injected with a small amount of rMuIFN-γ (102 U) and bacterial lipopolysaccharide (LPS) (10 ng) together at 6 h before the challenge, although the IFN-γ or LPS alone at these doses produced very little if any effect. Bactericidal effect enhancement was seen in mice that had been injected with IFN-γ at 6 h and LPS at 3 h before the challenge, while it could be hardly seen in mice injected with them in a reversed order. The simultaneous injections of rMuIFN-γ and LPS at 6 h in advance could confer a good protection against the infection with the S. tryphimurium LT2 strain.
UR - http://www.scopus.com/inward/record.url?scp=0025020413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025020413&partnerID=8YFLogxK
U2 - 10.1016/0192-0561(90)90067-W
DO - 10.1016/0192-0561(90)90067-W
M3 - Article
VL - 12
SP - 49
EP - 56
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
IS - 1
ER -